Julia Vitarello’s journey began when her daughter Mila was diagnosed with a rare genetic disease. In a pioneering effort, scientists created a bespoke medicine tailored to Mila’s specific mutation. Now, Vitarello is launching a new biotech to produce these individualized therapies on a larger scale. This Q&A explores the story, the challenges, and the future of personalized medicine.
Who is Julia Vitarello and what happened to her daughter Mila?
Julia Vitarello is the mother of Mila, a child born with a rare and devastating genetic disorder caused by a unique mutation. In 2015, at age six, Mila became the first patient to receive a custom-designed antisense oligonucleotide (ASO) therapy—often called a “bespoke” or “N-of-1” medicine—created specifically to target her exact genetic error. The drug, named milasen, stabilized her condition and opened a new frontier in precision medicine. Vitarello has since dedicated herself to making such personalized treatments available to other children with similarly rare mutations. Her story highlights both the promise and the immense complexity of delivering individualized therapies at scale.
What was EveryONE Medicines and why did it fold?
EveryONE Medicines was the biotech company Vitarello founded to advance the development of custom therapies for patients with unique genetic mutations. The company aimed to create a sustainable model for producing ASO drugs for individual patients. However, EveryONE Medicines recently ceased operations. According to Vitarello, a key reason was that the U.S. Food and Drug Administration’s updated guidance on customized therapies did not go far enough to create a clear regulatory and reimbursement pathway that could satisfy investors. Without that clarity, venture capital dried up, making it impossible to continue. The closure underscores the financial and regulatory hurdles that still hinder the field of personalized medicine.
What is Vitarello’s new company and how is it different?
Vitarello is now in the process of starting a new biotech company, though she has not yet publicly named it or revealed its full structure. The goal remains the same: to produce individualized therapies at scale, but with a refined strategy. This time, Vitarello and her collaborators are seeking different types of funders—possibly including philanthropists, patient advocacy groups, or government entities—rather than relying solely on traditional venture capital. They hope to build a platform that can efficiently design, test, and manufacture bespoke ASOs for multiple patients simultaneously, lowering costs and speeding up delivery. The new company will also work closely with the FDA to help shape the evolving regulatory landscape.
What are the main challenges in scaling bespoke medicines?
Scaling individualized therapies like milasen faces several obstacles. First, each drug must be designed from scratch for a single patient’s mutation, which is time-consuming and expensive—often costing millions per patient. Second, regulatory approval pathways are unclear: current FDA frameworks are built for one-drug-fits-all approvals, not for N-of-1 treatments. Third, manufacturing is custom and lacks economies of scale. Fourth, insurance reimbursement is uncertain, as payers are hesitant to cover such high-cost, unproven therapies. Finally, there is a scientific challenge: identifying which mutations are amenable to ASO therapy and validating each candidate quickly. Vitarello’s new biotech aims to tackle these issues through technological innovation and strategic partnerships.
What role does the FDA play in advancing or hindering these therapies?
The FDA has shown interest in fostering personalized medicine. In 2021, it issued draft guidance on “individualized antisense drugs” proposing a framework for developing and reviewing N-of-1 therapies. However, Vitarello argues that the guidance did not go far enough—it lacks explicit pathways for streamlined approval, clear endpoints, and reimbursement mechanisms. This regulatory uncertainty makes investors wary. On the positive side, the FDA has allowed some therapies to proceed under expanded access or clinical trials. Vitarello hopes that her new company, along with other advocates, can work with the FDA to refine these guidelines, creating a more predictable environment that encourages investment and ultimately benefits patients.
What is the broader significance of Mila’s story for rare disease patients?
Mila’s case is a landmark for rare disease treatment. It demonstrates that a therapy can be designed and deployed within months for an individual with a unique mutation, offering hope to families who previously had none. It has spurred a movement toward “N-of-1” medicine, where treatments are tailored to genetic specifics. For the estimated 300 million people worldwide with rare diseases—many of whom have ultra-rare mutations—this approach could be life-changing. However, it also raises questions about equity, cost, and sustainability. Vitarello’s ongoing efforts signal that the medical and biotech communities are beginning to take these challenges seriously, pushing for systemic changes that could make bespoke therapies a routine option.
What is the timeline for Vitarello’s new company and its first treatments?
As of the announcement in Rome, Vitarello is still in the early stages of fundraising and assembling a team. No specific timeline has been given for when the company will be operational or when its first patient therapies might be developed. Given the complexity of creating scalable platforms and navigating regulatory approvals, it could be several years before the company treats its first patient outside of Mila’s existing program. However, Vitarello and her collaborators are leveraging lessons from EveryONE Medicines to move more efficiently. They are also exploring collaborations with academic medical centers and patient registries to identify candidates early. Updates are expected as the company secures funding and begins preclinical work.